Over the past decade, messenger RNA (mRNA) has emerged as potent and flexible platform
for the development of novel effective cancer immunotherapies. Advances in non-viral gene …

Cancer immunotherapy has achieved remarkable success over the past decade by
modulating patients' own immune systems and unleashing pre-existing immunity. However …

As the sentinels of the immune system, dendritic cells (DCs) play a critical role in initiating
and regulating antigen-specific immune responses. Cross-priming, a process that DCs …

Malignant melanoma is one of the most aggressive forms of cancer and the leading cause of
death from skin tumors. Given the increased incidence of melanoma diagnoses in recent …

Introduction Cancer immunotherapy is more dependent on monoclonal antibodies, proteins,
and cells, as therapeutic agents, to attain prominent outcomes. However, cancer …

Cancer vaccines have recently garnered tremendous interest. However, the targeted
delivery of antigens and adjuvants to dendritic cells (DCs) still remains challenging. In this …

Extracellular vesicles (EVs) are cell-derived biological nanoparticles that gained great
interest for drug delivery. EVs have numerous advantages compared to synthetic …

Unlike traditional cancer therapies, such as surgery, radiation and chemotherapy that are
typically non-specific, cancer immunotherapy harnesses the high specificity of a patient's …

As the most potent professional antigen presenting cells, dendritic cells (DCs) have the
ability to activate both naive CD4 and CD8 T cells. Recognized for their exceptional ability to …

Peptide vaccines have shown great potential in cancer immunotherapy by targeting tumor
antigens and activating the patient's immune system to mount a specific response against …